Revenue
0
2019 Q4 ·
Fundies. English
KALARIS THERAPEUTICS, INC.
EDGAR40 filing records in this dataset, filed from 2020-07-06 to 2026-08-11. Reported financial figures are available; chart coverage varies by period.
Latest quarter
Operating cash flow
-8.87 million
2019 Q4 ·
Free cash flow
-8.99 million USD
2019 Q4 · USD
- Cash and cash equivalents
- 43.2 million USD Source
Exact value
43173000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 23.8 million shares Source
Exact value
23804981 shares
Reported share-count change
27.28% · 5.1 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Net income
-44.3 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-11.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: 1 of 11 periods available· newest 2019-12-31
- Operating income: 7 of 11 periods available· newest 2025-12-31
- Net income: 7 of 11 periods available· newest 2025-12-31
- Operating cash flow: 7 of 11 periods available· newest 2025-12-31
- Capital expenditure: 4 of 11 periods available· newest 2025-12-31
- Total assets: 7 of 11 periods available· newest 2025-12-31
- Total liabilities: 7 of 11 periods available· newest 2025-12-31
- Current assets: 7 of 11 periods available· newest 2025-12-31
- Current liabilities: 7 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 7 of 11 periods available· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: 7 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
+USD 25.73 millionPrior period
−USD 69.17 million
–
Current period
−USD 43.44 million
–
Exact inputs and evidence
-43438000 − -69167000 = 25729000 USD
-69167000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-43438000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 17.7 millionPrior period
−USD 20.7 million
–
Current period
−USD 38.4 million
–
Exact inputs and evidence
-38400000 − -20700000 = -17700000 USD
-20700000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-38400000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2019 2019-01-01 – 2019-12-31
- Revenue USD 165,000 100% of revenue
- Operating costs Derived USD 26.87 million 16,282% of revenue
- Operating income −USD 26.7 million −16,182% of revenue
- Tax, interest and other Derived −USD 2.86 million −1,735% of revenue
- Net income −USD 23.84 million −14,448% of revenue
Cash
- Operating cash flow −USD 20.16 million −12,215% of revenue
- Capital expenditure USD 339,000 205% of revenue
- Free cash flow Derived −USD 20.49 million −12,421% of revenue
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2019 Operating loss: operating costs were 16,282% of revenue.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2019 2019-01-01 – 2019-12-31 | 165000 | 26866000 Derived | -26701000 | -2862000 Derived | -23839000 | -20494000 Derived | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 165K 2019
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2019 | Revenue | 165000 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2019 | Year over year | No prior comparable period |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin -16,182.4% 2019
Net margin -14,447.9% 2019
Free cash flow margin -12,420.6% 2019
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2019 | Operating margin | -16,182.4% |
|
| 2019 | Net margin | -14,447.9% |
|
| 2019 | Free cash flow margin | -12,420.6% |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD -20.2M 2019
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2019 | Operating cash flow | -20155000 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
USD -20.5M 2019
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2019 | Free cash flow | -20494000 |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
12.8% 2019
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2019 | Liabilities / assets | 12.8% |
|
Current assets to current liabilities
Current assets divided by current liabilities.
13.98× 2019
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2019 | Current assets / current liabilities | 13.98× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2019 2019-01-01 – 2019-12-31 | −USD 23.84 million Exact valueExact value: -23839000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 20.16 million Exact valueExact value: -20155000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 339,000 Exact valueExact value: 339000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 20.49 million Calculation and evidence-20155000 − 339000 USD Exact free cash flow: -20494000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2020 2020-01-01 – 2020-12-31 | −USD 69.8 million Exact valueExact value: -69800000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 60.81 million Exact valueExact value: -60811000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 235,000 Exact valueExact value: 235000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 61.05 million Calculation and evidence-60811000 − 235000 USD Exact free cash flow: -61046000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2021 2021-01-01 – 2021-12-31 | −USD 172 million Exact valueExact value: -172000000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 106.32 million Exact valueExact value: -106319000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 26,000 Exact valueExact value: 26000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 106.35 million Calculation and evidence-106319000 − 26000 USD Exact free cash flow: -106345000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2022 2022-01-01 – 2022-12-31 | −USD 168.7 million Exact valueExact value: -168700000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 142.05 million Exact valueExact value: -142052000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2023-01-01 – 2023-12-31 | −USD 190.4 million Exact valueExact value: -190400000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 124.45 million Exact valueExact value: -124451000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | −USD 69.17 million Exact valueExact value: -69167000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 20.7 million Exact valueExact value: -20700000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | −USD 43.44 million Exact valueExact value: -43438000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 38.4 million Exact valueExact value: -38400000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 200,000 Exact valueExact value: 200000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 38.6 million Calculation and evidence-38400000 − 200000 USD Exact free cash flow: -38600000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
40 filings · 1,532 latest values · 1,532 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001754068, 1754068, ALVR, KLRS, edgar:1754068
Also known as ALLOVIR, INC., Allovir, Inc., KALARIS THERAPEUTICS, INC., Kalaris Therapeutics, Inc., ViraCyte, Inc.